ReviewVascular health and risk management2016

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives.

Holly E Gurgle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.